Novel and Traditional Cardiovascular Risk Factors for Peripheral Arterial Disease in Incident-Dialysis Patients

Advances in Chronic Kidney Disease

Volumn 14, Issue 3, 2007, Pages 304-313

  Jaar, Bernard G ^a,b,c   Plantinga, Laura C ^a   Astor, Brad C ^b   Fink, Nancy E ^a,b   Longenecker, Craig ^d   Tracy, Russell P ^e   Marcovina, Santica M ^f   Powe, Neil R ^a,b   Coresh, Josef ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NEPHROLOGY CENTER OF MARYLAND   (United States)

^d KUWAIT UNIVERSITY   (Kuwait)

^e UNIVERSITY OF VERMONT   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

C reactive protein; Dialysis; End stage renal disease; Fibrinogen; Homocysteine; Lipoprotein (a); Peripheral arterial disease; Prevalence; Risk factors

Indexed keywords

HOMOCYSTEINE; LIPOPROTEIN A;

ADULT; AGE; AGED; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR RISK; FEMALE; HEMODIALYSIS PATIENT; HUMAN; INCIDENCE; KIDNEY FAILURE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL;

ADULT; AGE DISTRIBUTION; AGED; ARTERIAL OCCLUSIVE DISEASES; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; ODDS RATIO; PERIPHERAL VASCULAR DISEASES; PREVALENCE; PROBABILITY; PROGNOSIS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; TREATMENT OUTCOME;

EID: 34250862685     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2007.04.005     Document Type: Article

References (45)

1. U.S. Renal Data System: USRDS 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
2. O'Hare A., and Johansen K. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol 12 (2001) 2838-2847
3. O'Hare A.M., Hsu C.Y., Bacchetti P., et al. Peripheral vascular disease risk factors among patients undergoing hemodialysis. J Am Soc Nephrol 13 (2002) 497-503
4. Cheung A.K., Sarnak M.J., Yan G., et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58 (2000) 353-362
5. Ridker P.M., Cushman M., Stampfer M.J., et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97 (1998) 425-428
6. Cheng S.W., Ting A.C., and Wong J. Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease. Ann Vasc Surg 11 (1997) 217-223
7. Cheng S.W., Ting A.C., and Wong J. Lipoprotein(a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. Eur J Vasc Endovasc Surg 14 (1997) 17-23
8. Miskulin D.C., Athienites N.V., Yan G., et al. Comorbidity assessment using the Index of Coexistent Diseases in a multi-center clinical trial. Kidney Int 60 (2001) 1498-1510
9. Athienites N.V., Miskulin D.C., Fernandez G., et al. Comorbidity assessment in hemodialysis and peritoneal dialysis using the index of coexistent disease. Semin Dial 13 (2000) 320-326
10. Macy E.M., Hayes T.E., and Tracy R.P. Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference intervals and epidemiological applications. Clin Chem 43 (1997) 52-58
11. Marcovina S.M., Albers J.J., Gabel B., et al. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 41 (1995) 246-255
12. Araki A., and Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 422 (1987) 43-52
13. Ridker P.M., Stampfer M.J., and Rifai N. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285 (2001) 2481-2485
14. Localio A.R., Berlin J.A., Ten Have T.R., et al. Adjustments for center in multicenter studies: an overview. Ann Intern Med 135 (2001) 112-123
15. U.S. Renal Data System: USRDS 1999 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
16. Criqui M.H. Peripheral arterial disease-epidemiological aspects. Vasc Med 6 (2001) 3-7
17. Stack A.G., and Bloembergen W.E. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: A cross-sectional study. J Am Soc Nephrol 12 (2001) 1516-1523
18. U.S. Renal Data System: USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
19. Fishbane S., Youn S., Flaster E., et al. Ankle-arm blood pressure index as a predictor of mortality in hemodialysis patients. Am J Kidney Dis 27 (1996) 668-672
20. Ono K., Tsuchida A., Kawai H., et al. Ankle-brachial blood pressure index predicts all-cause and cardiovascular mortality in hemodialysis patients. J Am Soc Nephrol 14 (2003) 1591-1598
21. Testa A., and Ottavioli J.N. Ankle-arm blood pressure index (AABPI) in hemodialysis patients. Arch Mal Coeur Vaiss 91 (1998) 963-965
22. Criqui M.H., Denenberg J.O., Langer R.D., et al. The epidemiology of peripheral arterial disease: Importance of identifying the population at risk. Vasc Med 2 (1997) 221-226
23. Lagrand W.K., Visser C.A., Hermens W.T., et al. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon?. Circulation 100 (1999) 96-102
24. Aboyans V., Criqui M.H., Denenberg J.O., et al. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 113 (2006) 2623-2629
25. Yeun J., Levine R., Mantadilok V., et al. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35 (2000) 469-476
26. Boger C.A., Gotz A., Stubanus M., et al. C-reactive protein as predictor of death in end-stage diabetic nephropathy: Role of peripheral arterial disease. Kidney Int 68 (2005) 217-227
27. Jauhiainen M., Koskinen P., Ehnholm C., et al. Lipoprotein(a) and coronary heart disease risk: A nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 89 (1991) 59-67
28. Ridker P.M., Hennekens C.H., and Stampfer M.J. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 270 (1993) 2195-2199
29. Tseng C.H. Lipoprotein(a) is an independent risk factor for peripheral arterial disease in Chinese type 2 diabetic patients in Taiwan. Diabetes Care 27 (2004) 517-521
30. Auguet T., Senti M., Rubies-Prat J., et al. Serum lipoprotein(a) concentration in patients with chronic renal failure receiving haemodialysis: Influence of apolipoprotein(a) genetic polymorphism. Nephrol Dial Transplant 8 (1993) 1099-1103
31. Dieplinger H., Lackner C., Kronenberg F., et al. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 91 (1993) 397-401
32. Kronenberg F., Konig P., Neyer U., et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 6 (1995) 110-120
33. Longenecker J.C., Klag M.J., Marcovina S.M., et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in eialysis patients. J Am Soc Nephrol 16 (2005) 1794-1802
34. Lye W.C., Hughes K., Leong S.O., et al. Lipoprotein (a) levels and clinical correlations in CAPD patients. Adv Perit Dial 11 (1995) 131-133
35. Kronenberg F., Mundle M., Langle M., et al. Prevalence and progression of peripheral arterial calcifications in patients with ESRD. Am J Kidney Dis 41 (2003) 140-148
36. Bostom A.G., Shemin D., Verhoef P., et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study. Arterioscler Thromb Vasc Biol 17 (1997) 2554-2558
37. McCully K.S. Homocysteine and vascular disease. Nat Med 2 (1996) 386-389
38. Boushey C.J., Beresford S.A., Omenn G.S., et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 274 (1995) 1049-1057
39. Graham I.M., Daly L.E., Refsum H.M., et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 277 (1997) 1775-1781
40. Bostom A.G., and Lathrop L. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 52 (1997) 10-20
41. Moustapha A., Gupta A., Robinson K., et al. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int 55 (1999) 1470-1475
42. Chauveau P., Chadefaux B., Coude M., et al. Increased plasma homocysteine concentration in patients with chronic renal failure. Miner Electrolyte Metab 18 (1992) 196-198
43. Bachmann J., Tepel M., Raidt H., et al. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 6 (1995) 121-125
44. Robinson K., Gupta A., Dennis V., et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94 (1996) 2743-2748
45. Manns B., Burgess E., Hyndman M.E., et al. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am J Kidney Dis 34 (1999) 669-677